isophosphoramide mustard

Palifosfamide (Isophosphamide mustard) lysine (ZIO-201) is a stable form of palifosfamide. Palifosfamide lysine has broad activity in sarcoma lines in vitro. The IC50 ranges from 2.25 to 6.75 μM for most cell lines except OS222 (IC50=31.5 μM).

FLB-457 is a dopamine antagonist.

Evofosfamide (TH-302) is a hypoxia-activated prodrug of the cytotoxin bromo-isophosphoramide mustard (Br-IPM) conjugated with 2-nitroimidazole, possessing potential antineoplastic activity. Under hypoxic conditions, typical of hypoxic tumors, the 2-nitroimidazole moiety is reduced, releasing the DNA-alkylating Br-IPM moiety, which induces intra- and inter-strand DNA crosslinks that inhibit DNA replication and cell division, potentially causing apoptosis in tumor cells. The inactive form of the prodrug remains stable under normoxic conditions, which may reduce systemic toxicity.

Palifosfamide (tromethamine), a synthetically derived alkylating agent, exhibits potential antineoplastic properties. Acting as the stabilized active metabolite of ifosfamide, it irreversibly alkylates and crosslinks DNA at GC base pairs, inhibiting DNA replication and inducing cell death. Palifosfamide (tromethamine) boasts reduced toxicity in comparison to ifosfamide.